As of 06 Nov 2026 06:08 UTC. Status is always as stated in the latest recorded notice; the sources do not publish resolution, so nothing on this page says a medicine is back — see methodology.
Presentations, as stated in the latest recorded notice
Each line is re-expressed from MSN/2024/113 (13 Dec 2024): the product named, the status the source stated, and the expected-back phrase kept as written. Not the source's sentence, and not an observation of stock.
| Presentation | Status, as stated | Expected back, as stated | Stated in |
|---|---|---|---|
| Cefalexin 125mg/5ml and 250mg/5ml oral suspension (sugar free)affected product · inferred from phrasing | Out of stock, as stated | — not stated for this line | notice of 13 Dec 2024 |
| Cefalexin 125mg/5ml and 250mg/5ml oral suspension (non sugar free)named by the source as remaining available · inferred from phrasing | Stated as available | — not stated for this line | notice of 13 Dec 2024 |
Protocol in force
No Serious Shortage Protocol matched to this name is in force on the NHSBSA register — 3 earlier protocols on this record have expired: SSP078 (to 28 Nov 2025), SSP077 (to 28 Nov 2025), SSP072 (to 27 Sep 2024). Matching is by name until identifier coding lands.
Named in the source as remaining available
- Cefalexin 125mg/5ml and 250mg/5ml oral suspension (non sugar free) — named by the source as remaining available (inferred from phrasing)
Only names the source itself listed, as it listed them (source post ↗). No substitution, dosing or counselling advice is given here or implied.
Identifiers — Cefalexin
BNF chemical and SNOMED identifiers from NHSBSA Prescription Cost Analysis (Open Government Licence), matched by name (presentation name), confidence 0.90 — grouping under review where marked Release Jul 2026.
BNF SNOMED mapping, NHSBSA Copyright 2026; Prescription Cost Analysis (PCA) Monthly Administrative Data, NHSBSA Copyright 2026. This information is licenced under the terms of the Open Government Licence.
History
Notified short 3 times on record since 2024. We record when a shortage is declared, not when stock returns — the source doesn't publish that. An update sharing a reference counts as one episode.
| Issued | Notice | Kind | Tier | Reference |
|---|---|---|---|---|
| 13 Dec 2024 | Medicine Supply Notification: Cefalexin 125mg/5ml and 250mg/5ml oral suspensions, sugar free | Supply notification | Tier 2 | MSN/2024/113 |
| 06 Aug 2024 | Medicine Supply Notification: Cefalexin 500mg tablets | Supply notification | Tier 2 | MSN/2024/083 |
| 10 Apr 2024 | Medicine Supply Notification: Cefalexin 125mg/5ml and 250mg/5ml oral suspension | Supply notification | Tier 2 | MSN/2024/041 |
Also recorded under
No other name appears in this medicine's notice titles. Grouping is by the head name in each title; brand and generic names may still sit on separate pages until identifier coding refines it — see the A–Z.
Scotland — separate record
NHS Scotland issues its own Medicine Supply Alert Notices. These match this medicine's name; they are shown beside, never added to, the England record.
- MSAN(2024)67 Cefalexin 125mg/5ml and 250mg/5ml oral suspensions, sugar free · issued 27 Dec 2024 · valid until mid-2025, as stated · matched by name PDF ↗
- MSAN(2024)47 Cefalexin 500mg tablets · issued 09 Aug 2024 · valid until late September 2024, as stated · matched by name PDF ↗